Cell adhesion and long-term survival of transplanted mesenchymal stem cells: A prerequisite for cell therapy

Oxidative Medicine and Cellular Longevity

Volumn 2015, Issue , 2015, Pages

  Lee, Seahyoung ^a   Choi, Eunhyun ^a   Cha, Min Ji ^a   Hwang, Ki Chul ^a  

^a Catholic Kwandong University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION; CELL CULTURE; CELLS; CYTOLOGY; DISEASE CONTROL; FLOWCHARTING; STEM CELLS; TISSUE REGENERATION;

APOPTOTIC SIGNALING; BENEFICIAL EFFECTS; CLINICAL APPLICATION; DEGENERATIVE DISEASE; GENETIC MODIFICATIONS; MESENCHYMAL STEM CELL; MICROENVIRONMENTS; THERAPEUTIC POTENTIALS;

CELL SIGNALING;

HEAT SHOCK PROTEIN 27;

ANOIKIS; CELL ADHESION; CELL DEATH; CELL RENEWAL; CELL STRESS; CELL SURVIVAL; DNA MODIFICATION; HUMAN; HYPOXIA; LONG TERM SURVIVAL; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; REVIEW; APOPTOSIS; BIOLOGICAL THERAPY; CYTOLOGY; MESENCHYMAL STROMA CELL; REGENERATION;

ANIMALIA;

APOPTOSIS; CELL ADHESION; CELL- AND TISSUE-BASED THERAPY; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; REGENERATION;

EID: 84923879592     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2015/632902     Document Type: Review

References (103)

1. C. Mason, D. A. Brindley, E. J. Culme-Seymour, and N. L. Davie, "Cell therapy industry: billion dollar global businesswith unlimited potential," Regenerative Medicine, vol. 6, no. 3, pp. 265-272, 2011.
2. B. E. Strauer and R. Kornowski, "Stem cell therapy in perspective," Circulation, vol. 107, no. 7, pp. 929-934, 2003.
3. K. R. Brunt, R. D. Weisel, and R.-K. Li, "Stem cells and regenerative medicine-future perspectives," Canadian Journal of Physiology and Pharmacology, vol. 90,no. 3, pp. 327-335, 2012.
4. K. Takahashi and S. Yamanaka, "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors," Cell, vol. 126, no. 4, pp. 663-676, 2006.
5. K. Takahashi, K. Tanabe, M. Ohnuki et al., "Induction of pluripotent stem cells from adult human fibroblasts by defined factors," Cell, vol. 131, no. 5, pp. 861-872, 2007.
6. S. M. Wu and K. Hochedlinger, "Harnessing the potential of induced pluripotent stem cells for regenerative medicine," Nature Cell Biology, vol. 13, no. 5, pp. 497-505, 2011.
7. C. A. Herberts, M. S. G. Kwa, and H. P. H. Hermsen, "Risk factors in the development of stem cell therapy," Journal of Translational Medicine, vol. 9, article 29, 2011.
8. E. C. Perin, Y.-J. Geng, and J. T. Willerson, "Adult stem cell therapy in perspective," Circulation, vol. 107, no. 7, pp. 935-938, 2003.
9. A. Pessina and L. Gribaldo, "The key role of adult stem cells: therapeutic perspectives," Current Medical Research and Opinion, vol. 22, no. 11, pp. 2287-2300, 2006.
10. F. P. Barry and J. M. Murphy, "Mesenchymal stem cells: clinical applications and biological characterization," International Journal of Biochemistry and Cell Biology, vol. 36, no. 4, pp. 568-584, 2004.
11. G. Makhoul, R. C. J. Chiu, and R. Cecere, "Placental mesenchymal stem cells: a unique source for cellular cardiomyoplasty," Annals ofThoracic Surgery, vol. 95, no. 5, pp. 1827-1833, 2013.
12. A.M. DiMarino, A. I. Caplan, and T. L. Bonfield, "Mesenchymal stem cells in tissue repair," Frontiers in Immunology, vol. 4, article 201, 2013.
13. F. Djouad, C. Bouffi, S. Ghannam, D. Noël, and C. Jorgensen, "Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases," Nature Reviews Rheumatology, vol. 5, no. 7, pp. 392-399, 2009.
14. S. M. Devine, A. M. Bartholomew, N. Mahmud et al., "Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion," Experimental Hematology, vol. 29, no. 2, pp. 244-255, 2001.
15. N. Mahmud, W. Pang, C. Cobbs et al., "Studies of the route of administration and role of conditioning with radiation on unrelated allogeneic mismatched mesenchymal stem cell engraftment in a nonhuman primate model," Experimental Hematology, vol. 32, no. 5, pp. 494-501, 2004.
16. P. Semedo,M. Burgos-Silva, C. Donizetti-Oliveira, and N. O. S. Camara, "Howdomesenchymal stemcells repair?" in StemCells in Clinic and Research, A. Gholamrezanezhad, Ed., pp. 83-104, InTech, 2011.
17. C. Conrad, S. Lechner, H. Niess, and R. Huss, "Basic biology and animal models in stem cell-mediated tissue regeneration," in Topics in Tissue Engineering, N. Ashammakhi, R. Reis, and E. Chiellini, Eds., vol. 3, 2007.
18. A. Trounson, R.G. Thakar,G. Lomax, and D. Gibbons, "Clinical trials for stem cell therapies," BMC Medicine, vol. 9, article 52, 2011.
19. S. Wang,X. Qu, and R.C. Zhao, "Clinical applications of mesenchymal stem cells," Journal ofHematology&Oncology, vol. 5, no. 1, article 19, 2012.
20. K. Le Blanc, F. Frassoni, L. Ball et al., "Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versushost disease: a phase II study," The Lancet, vol. 371, no. 9624, pp. 1579-1586, 2008.
21. K. Le Blanc, C. Götherström, O. Ringdén et al., "Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta," Transplantation, vol. 79, no. 11, pp. 1607-1614, 2005.
22. O. N. Koç, J. Day, M. Nieder, S. L. Gerson, H. M. Lazarus, and W. Krivit, "Allogeneic mesenchymal stem cell infusion for treatment ofmetachromatic leukodystrophy (MLD) andHurler syndrome (MPS-IH)," Bone Marrow Transplantation, vol. 30, no. 4, pp. 215-222, 2002.
23. N. Meuleman,G. Vanhaelen, T. Tondreauet al., "Reduced intensity conditioning haematopoietic stem cell transplantation with mesenchymal stromal cells infusion for the treatment of metachromatic leukodystrophy: a case report," Haematologica, vol. 93, no. 1, pp. e11-e13, 2008.
24. J. S. Da Silva and J. M. Hare, "Cell-based therapies for myocardial repair: emerging role for bone marrow-derived mesenchymal stem cells (MSCs) in the treatment of the chronically injured heart," Methods in Molecular Biology, vol. 1037, pp. 145-163, 2013.
25. W. Chang, B.-W. Song, and K.-C. Hwang, "Mesenchymal stem cell survival in infarcted myocardium: adhesion and anti-death signals," in Stem Cells and Cancer Stem Cells, vol. 10, pp. 35-43, Springer, Dordrecht, The Netherlands, 2013.
26. J.-B. Michel, "Anoïkis in the cardiovascular system: known and unknown extracellular mediators," Arteriosclerosis,Thrombosis, and Vascular Biology, vol. 23, no. 12, pp. 2146-2154, 2003.
27. M. L. Taddei, E. Giannoni, T. Fiaschi, and P. Chiarugi, "Anoikis: an emerging hallmark in health and diseases," The Journal of Pathology, vol. 226, no. 2, pp. 380-393, 2012.
28. A. K. Santos, F. M. Tonelli, D. A. Silva, K. N. Gomes, L. O. Ladeira, and R. R. Resende, "The role of cell adhesion, cell junctions, and extracellular matrix in development and carcinogenesis," in Trends in Stem Cell Proliferation and Cancer Research, pp. 13-49, Springer, 2013.
29. P.-L. Mok, C.-F. Leong, and S.-K. Cheong, "Cellular mechanisms of emerging applications of mesenchymal stem cells," Malaysian Journal of Pathology, vol. 35, no. 1, pp. 17-32, 2013.
30. R. A. Webster, S. P. Blaber, B. R. Herbert, M. R. Wilkins, and G. Vesey, "The role of mesenchymal stem cells in veterinary therapeutics-a review," New Zealand Veterinary Journal, vol. 60, no. 5, pp. 265-272, 2012.
31. I. Singec and E. Y. Snyder, "Inflammation as a matchmaker: revisiting cell fusion," Nature Cell Biology, vol. 10,no. 5, pp. 503-505, 2008.
32. K. Kemp, D. Gordon, D. C. Wraith et al., "Fusion between human mesenchymal stem cells and rodent cerebellar Purkinje cells," Neuropathology and Applied Neurobiology, vol. 37, no. 2, pp. 166-178, 2011.
33. A. Cselenyák, E. Pankotai, E. M. Horváth, L. Kiss, and Z. Lacza, "Mesenchymal stem cells rescue cardiomyoblasts from cell death in an in vitro ischemia model via direct cell-to-cell connections," BMC Cell Biology, vol. 11, article 29, 2010.
34. M. Alvarez-Dolado, R. Pardal, J. M. Garcia-Verdugo et al., "Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes," Nature, vol. 425, no. 6961, pp. 968-973, 2003.
35. S.C. Smith Jr., A. Collins, D. Chen et al., "Moving frompolitical declaration to action on reducing the global burden of cardiovascular diseases: a statement fromthe Global Cardiovascular Disease Taskforce," European Heart Journal, vol. 34, no. 46, pp. 3526-3528, 2013.
36. E. M. Horwitz, D. J. Prockop, L. A. Fitzpatrick et al., "Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta," Nature Medicine, vol. 5, no. 3, pp. 309-313, 1999.
37. F. G. Teixeira, M. M. Carvalho, N. Sousa, and A. J. Salgado, "Mesenchymal stem cells secretome: a newparadigmfor central nervous system regeneration?" Cellular and Molecular Life Sciences, vol. 70, no. 20, pp. 3871-3882, 2013.
38. A. M. Hocking and N. S. Gibran, "Mesenchymal stem cells: paracrine signaling and differentiation during cutaneous wound repair," Experimental Cell Research, vol. 316, no. 14, pp. 2213-2219, 2010.
39. M. Gnecchi, Z. P. Zhang, A. G. Ni, and V. J. Dzau, "Paracrine mechanisms in adult stem cell signaling and therapy," Circulation Research, vol. 103, no. 11, pp. 1204-1219, 2008.
40. H.O. Kim, S.-M. Choi, and H.-S. Kim, "Mesenchymal stem cellderived secretome and microvesicles as a cell-free therapeutics for neurodegenerative disorders," Tissue Engineering and Regenerative Medicine, vol. 10, no. 3, pp. 93-101, 2013.
41. S. H. Ranganath, O. Levy, M. S. Inamdar, and J. M. Karp, "Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease," Cell Stem Cell, vol. 10, no. 3, pp. 244-258, 2012.
42. L. Ionescu, R. N. Byrne, T. van Haaften et al., "Stem cell conditioned medium improves acute lung injury in mice: in vivo evidence for stem cell paracrine action," American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 303, no. 11, pp. L967-L977, 2012.
43. I. Kim, S. K. Lee, J. I. Yoon, D. E. Kim, M. Kim, and H. Ha, "Fibrin glue improves the therapeutic effect of MSCs by sustaining survival and paracrine function," Tissue Engineering, Part A, vol. 19, no. 21-22, pp. 2373-2381, 2013.
44. R. Abdi, P. Fiorina, C. N. Adra, M. Atkinson, and M. H. Sayegh, "Immunomodulation by mesenchymal stem cells-a potential therapeutic strategy for type 1 diabetes," Diabetes, vol. 57, no. 7, pp. 1759-1767, 2008.
45. M. J. Hoogduijn, F. Popp, R. Verbeek et al., "The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy," International Immunopharmacology, vol. 10, no. 12, pp. 1496-1500, 2010.
46. A. I. Hoch, B. Y. Binder, D. C. Genetos, and J. K. Leach, "Differentiation-dependent secretion of proangiogenic factors by mesenchymal stem cells," PLoS ONE, vol. 7, no. 4,Article ID e35579, 2012.
47. A. Garg and P. N. Newsome, "Bone marrow mesenchymal stem cells and liver regeneration: believe the hypoxia," Stem Cell Research andTherapy, vol. 4, article 108, 2013.
48. A.N. He, Y. Jiang, C. Gui, Y. Sun, J.H. Li, and J.-A. Wang, "The antiapoptotic effect of mesenchymal stem cell transplantation on ischemic myocardium is enhanced by anoxic preconditioning," Canadian Journal of Cardiology, vol. 25, no. 6, pp. 353-358, 2009.
49. J. H. Li, N. Zhang, and J. A. Wangi, "Improved anti-apoptotic and anti-remodeling potency of bone marrow mesenchymal stem cells by anoxic pre-conditioning in diabetic cardiomyopathy," Journal of Endocrinological Investigation, vol. 31, no. 2, pp. 103-110, 2008.
50. T. Tsubokawa, K. Yagi, C. Nakanishi et al., "Impact of antiapoptotic and anti-oxidative effects of bone marrow mesenchymal stem cells with transient overexpression of heme oxygenase-1 onmyocardial ischemia (vol. 298, p. H1320, 2010)," The American Journal of Physiology-Heart and Circulatory Physiology, vol. 303, no. 4, p.H496, 2012.
51. A. Valle-Prieto and P. A. Conget, "Human mesenchymal stem cells efficiently manage oxidative stress," Stem Cells and Development, vol. 19, no. 12, pp. 1885-1893, 2010.
52. R. H. Lee, A. A. Pulin, M. J. Seo et al., "Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6," Cell Stem Cell, vol. 5, no. 1, pp. 54-63, 2009.
53. K.-S. Park, Y.-S. Kim, J.-H. Kim et al., "Trophic molecules derived fromhuman mesenchymal stem cells enhance survival, function, and angiogenesis of isolated islets after transplantation," Transplantation, vol. 89, no. 5, pp. 509-517, 2010.
54. G. Uzun, D. Subhani, and S. Amor, "Trophic factors and stem cells for promoting recovery in stroke," Journal of Vascular and Interventional Neurology, vol. 3, no. 1, pp. 3-12, 2010.
55. S. Bruno, C. Grange, F. Collino et al., "Microvesicles derived frommesenchymal stem cells enhance survival in a lethalmodel of acute kidney injury," PLoSONE, vol. 7, no. 3,Article IDe33115, 2012.
56. L. Biancone, S. Bruno, M. C. Deregibus, C. Tetta, and G. Camussi, "Therapeutic potential of mesenchymal stem cellderived microvesicles," Nephrology Dialysis Transplantation, vol. 27, no. 8, pp. 3037-3042, 2012.
57. M. Z. Ratajczak, "The emerging role of microvesicles in cellular therapies for organ/tissue regeneration," Nephrology Dialysis Transplantation, vol. 26, no. 5, pp. 1453-1456, 2011.
58. L. deGirolamo, E. Lucarelli, G. Alessandri et al., "Mesenchymal stem/stromal cells: a new 'cells as drugs' paradigm. Efficacy and critical aspects in cell therapy," Current Pharmaceutical Design, vol. 19, no. 13, pp. 2459-2473, 2013.
59. D. Drago, C. Cossetti, N. Iraci et al., "The stem cell secretome and its role in brain repair," Biochimie, vol. 95, no. 12, pp. 2271-2285, 2013.
60. E. Mathieu, G. Lamirault, C. Toquet et al., "Intramyocardial delivery of mesenchymal stem cell-seeded hydrogel preserves cardiac function and attenuates ventricular remodeling after myocardial infarction," PLoS ONE, vol. 7, no. 12, Article ID e51991, 2012.
61. T. E. Robey, M. K. Saiget, H. Reinecke, and C. E. Murry, "Systems approaches to preventing transplanted cell death in cardiac repair," Journal of Molecular and Cellular Cardiology, vol. 45, no. 4, pp. 567-581, 2008.
62. M. F. Pittenger, A. M. Mackay, S. C. Beck et al., "Multilineage potential of adult human mesenchymal stem cells," Science, vol. 284, no. 5411, pp. 143-147, 1999.
63. M. Majzunova, I. Dovinova, M. Barancik, and J. Y. H. Chan, "Redox signaling in pathophysiology of hypertension," Journal of Biomedical Science, vol. 20, no. 1, article 69, 2013.
64. H. Song, M.-J. Cha, B.-W. Song et al., "Reactive oxygen species inhibit adhesion of mesenchymal stem cells implanted into ischemic myocardium via interference of focal adhesion complex," Stem Cells, vol. 28, no. 3, pp. 555-563, 2010.
65. W. Chang, B.-W. Song, J.-Y. Moon et al., "Anti-death strategies against oxidative stress in grafted mesenchymal stem cells," Histology and Histopathology, vol. 28,no. 12,pp. 1529-1536, 2013.
66. N. Khansari, Y. Shakiba, and M. Mahmoudi, "Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer," Recent Patents on Inflammation & Allergy Drug Discovery, vol. 3, no. 1, pp. 73-80, 2009.
67. K. Urish, Inflammation and Stem Cell Transplantation, University of Pittsburgh, 2007.
68. J.-Y. Hahn, H.-J. Cho, H.-J. Kang et al., "Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction," Journal of the American College of Cardiology, vol. 51, no. 9, pp. 933-943, 2008.
69. G. Lu, H. K. Haider, S. Jiang, and M. Ashraf, "Sca-1+ stem cell survival and engraftment in the infarcted heart: dual role for preconditioning-induced connexin-43," Circulation, vol. 119, no. 19, pp. 2587-2596, 2009.
70. Z. Pasha, Y. Wang, R. Sheikh,D. Zhang, T. Zhao, and M. Ashraf, "Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium," Cardiovascular Research, vol. 77, no. 1, pp. 134-142, 2008.
71. W. Chang, B.-W. Song, S. Lim et al., "Mesenchymal stem cells pretreated with delivered Hph-1-Hsp70 protein are protected from hypoxia-mediated cell death and rescue heart functions frommyocardial injury," StemCells, vol. 27,no. 9, pp.2283-2292, 2009.
72. H. Song, B.-W. Song, M.-J. Cha, I.-G. Choi, and K.-C. Hwang, "Modification of mesenchymal stem cells for cardiac regeneration," Expert Opinion on Biological Therapy, vol. 10, no. 3, pp. 309-319, 2010.
73. X. Hu, S. P. Yu, J. L. Fraser et al., "Transplantation of hypoxiapreconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis," Journal of Thoracic and Cardiovascular Surgery, vol. 135, no. 4, pp. 799-808, 2008.
74. J. Yu, S. Yin, W. Zhang et al., "Hypoxia preconditioned bone marrowmesenchymal stem cells promote liver regeneration in a ratmassive hepatectomymodel," Stem Cell Research &Therapy, vol. 4, no. 4, article 83, 2013.
75. S.M. Chacko, S. Ahmed, K. Selvendiran, M. L. Kuppusamy, M. Khan, and P. Kuppusamy, "Hypoxic preconditioning induces the expression of prosurvival and proangiogenic markers in mesenchymal stem cells," American Journal of Physiology-Cell Physiology, vol. 299, no. 6, pp. C1562-C1570, 2010.
76. C.-P. Chang, C.-C. Chio, C.-U. Cheong, C.-M. Chao, B.-C. Cheng, and M.-T. Lin, "Hypoxic preconditioning enhances the therapeutic potential of the secretome from cultured human mesenchymal stem cells in experimental traumatic brain injury," Clinical Science, vol. 124, no. 3, pp. 165-176, 2013.
77. A. Mishra, P. Tummala, A. King et al., "Buffered platelet-rich plasma enhances mesenchymal stem cell proliferation and chondrogenic differentiation," Tissue Engineering. Part C,Methods, vol. 15, no. 3, pp. 431-435, 2009.
78. S. S. Lin, R. Landesberg, H. S. Chin, J. Lin, S. B. Eisig, and H. H. Lu, "Controlled release of PRP-derived growth factors promotes osteogenic differentiation of human mesenchymal stem cells," in Proceedings of the 28th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBS '06), pp. 4358-4361, New York, NY, USA, August-September 2006.
79. Y. Peng, S. Huang, Y. Wu et al., "Platelet rich plasma clot releasate preconditioning induced PI3K/AKT/NFκB signaling enhances survival and regenerative function of rat bone marrow mesenchymal stem cells in hostile microenvironments," Stem Cells and Development, vol. 22, no. 24, pp. 3236-3251, 2013.
80. B.-W. Song, W. Chang, B.-K. Hong et al., "Protein kinase C activation stimulates mesenchymal stem cell adhesion through activation of focal adhesion kinase," Cell Transplantation, vol. 22, no. 5, pp. 797-809, 2013.
81. X. Yu, D.M. Cohen, and C. S. Chen, "miR-125b is an adhesionregulated microRNA that protects mesenchymal stem cells from anoikis," Stem Cells, vol. 30, no. 5, pp. 956-964, 2012.
82. L. Song, Y.-J. Yang, Q.-T. Dong et al., "Atorvastatin enhance efficacy of mesenchymal stem cells treatment for swinemyocardial infarction via activation of nitric oxide synthase," PLoS ONE, vol. 8, no. 5, Article ID e65702, 2013.
83. Y. Tang, B. Cai, F. Yuan et al., "Melatonin pretreatment improves the survival and function of transplanted mesenchymal stem cells after focal cerebral ischemia," Cell Transplantation, vol. 23, no. 10, pp. 1279-1291, 2014.
84. F. Huang, M.-L. Li, Z.-F. Fang et al., "Overexpression of MicroRNA-1 improves the efficacy of mesenchymal stem cell transplantation after myocardial infarction," Cardiology, vol. 125, no. 1, pp. 18-30, 2013.
85. B.D. Brewster, J. D. Rouch,M. Wang, and D. R. Meldrum, "Tolllike receptor 4 ablation improves stem cell survival after hypoxic injury," Journal of Surgical Research, vol. 177, no. 2, pp. 330-333, 2012.
86. Y. Wang, A.M. Abarbanell, J.L. Herrmann et al., "TLR4 inhibits mesenchymal stem cell (MSC) STAT3 activation and thereby exerts deleterious effects on MSC-mediated cardioprotection," PLoS ONE, vol. 5, no. 12, Article IDe14206, 2010.
87. A. A. Mangi, N. Noiseux, D. Kong et al., "Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts," Nature Medicine, vol. 9, no. 9, pp. 1195-1201, 2003.
88. L. M. McGinley, J. McMahon, A. Stocca et al., "Mesenchymal stem cell survival in the infarcted heart is enhanced by lentivirus vector-mediated heat shock protein 27 expression," Human GeneTherapy, vol. 24, no. 10, pp. 840-851, 2013.
89. X. Wang, T. Zhao, W. Huang et al., "Hsp20-engineered mesenchymal stem cells are resistant to oxidative stress via enhanced activation of Akt and increased secretion of growth factors," Stem Cells, vol. 27, no. 12, pp. 3021-3031, 2009.
90. W. Li,N. Ma, L.-L. Ong et al., "Bcl-2 engineered MSCs inhibited apoptosis and improved heart function," Stem Cells, vol. 25, no. 8, pp. 2118-2127, 2007.
91. N. Liu, Y. Zhang, L. Fan et al., "Effects of transplantation with bone marrow-derived mesenchymal stem cells modified by Survivin on experimental stroke in rats," Journal of Translational Medicine, vol. 9, article 105, 2011.
92. L. Fan, C. Lin, S. Zhuo et al., "Transplantation with survivinengineered mesenchymal stem cells results in better prognosis in a rat model of myocardial infarction," European Journal of Heart Failure, vol. 11, no. 11, pp. 1023-1030, 2009.
93. J. Huang, Z. Zhang, J. Guo et al., "Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium," Circulation Research, vol. 106, no. 11, pp. 1753-1762, 2010.
94. C. Xiaowei, M. Jia,W. Xiaowei, and Z. Yina, "Overexpression of CXCL12 chemokine up-regulates connexin and integrin expression in mesenchymal stem cells through PI3K/Akt pathway," Cell Communication and Adhesion, vol. 20, no. 3-4, pp. 67-72, 2013.
95. I. B. Copland, S. Lord-Dufour, J. Cuerquis et al., "Improved autograft survival of mesenchymal stromal cells by plasminogen activator inhibitor 1 inhibition," Stem Cells, vol. 27, no. 2, pp. 467-477, 2009.
96. S. S. Akimov, D. Krylov, L. F. Fleischmana, and A. M. Belkin, "Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin,"The Journal of Cell Biology, vol. 148, no. 4, pp. 825-838, 2000.
97. H. Song, W. Chang, S. Lim et al., "Tissue transglutaminase is essential for integrin-mediated survival of bone marrowderived mesenchymal stem cells," Stem Cells, vol. 25, no. 6, pp. 1431-1438, 2007.
98. D. S.W. Benoit,M. C. Tripodi, J. O. Blanchette, S. J. Langer, L. A. Leinwand, and K. S. Anseth, "Integrin-linked kinase production prevents anoikis in human mesenchymal stem cells," Journal of Biomedical Materials Research, A, vol. 81, no. 2, pp. 259-268, 2007.
99. S.-W. Song,W. Chang, B.-W. Song et al., "Integrin-linked kinase is required in hypoxic mesenchymal stem cells for strengthening cell adhesion to ischemic myocardium," Stem Cells, vol. 27, no. 6, pp. 1358-1365, 2009.
100. S. Kidd, E. Spaeth, J. L. Dembinski et al., "Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging," Stem Cells, vol. 27, no. 10, pp. 2614-2623, 2009.
101. E. Spaeth, A. Klopp, J. Dembinski, M. Andreeff, and F. Marini, "Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells," GeneTherapy, vol. 15, no. 10, pp. 730-738, 2008.
102. C. D. Porada and G. Almeida-Porada, "Mesenchymal stem cells as therapeutics and vehicles for gene and drug delivery," Advanced Drug Delivery Reviews, vol. 62, no. 12, pp. 1156-1166, 2010.
103. D. Gjorgieva, N. Zaidman, and D. Bosnakovski, "Mesenchymal stem cells for anti-cancer drug delivery," Recent Patents on Anti- Cancer Drug Discovery, vol. 8, no. 3, pp. 310-318, 2013.